LNDC earnings

Lifecore segment revenues increased 8.0% to $23.7 million in fiscal 2023 first quarter versus the prior year periodLifecore segment EBITDA increased 8.1% to $2.5 million in fiscal 2023 first quarter versus the prior year periodReiterates fiscal 2023 full year guidance for LifecoreCorporate rebranding to Lifecore Biomedical continues to progress SANTA MARIA, Calif. and MINNEAPOLIS, Oct. 06, 2022 (GLOBE NEWSWIRE) -- Landec Corporation (NASDAQ:LNDC) ("Landec" or the "Company"), a diversified health and wellness company with two operating businesses, Lifecore Biomedical, Inc. ("Lifecore") and Curation Foods, Inc. ("Curation Foods"), reported results for the fiscal 2023 first

SANTA MARIA, Calif. and MINNEAPOLIS, Sept. 28, 2022 (GLOBE NEWSWIRE) -- Landec Corporation (NASDAQ:LNDC) ("Landec" or the "Company"), a diversified health and wellness company focused on its growing Lifecore Biomedical ("Lifecore") business – a fully integrated contract development and manufacturing organization ("CDMO") that offers highly differentiated capabilities in the development, fill and finish of complex sterile injectable pharmaceutical products in syringes and vials – today announced a change to its previously announced fiscal 2023 first quarter earnings conference call date in recognition of Yom Kippur. The Company will now report financial results before the market opens on T

SANTA MARIA, Calif. and MINNEAPOLIS, Sept. 21, 2022 (GLOBE NEWSWIRE) -- Landec Corporation (NASDAQ:LNDC) ("Landec" or the "Company"), a diversified health and wellness company focused on its growing Lifecore Biomedical ("Lifecore") business – a fully integrated contract development and manufacturing organization ("CDMO") that offers highly differentiated capabilities in the development, fill and finish of complex sterile injectable pharmaceutical products in syringes and vials – today announced that it will host a conference call to discuss fiscal 2023 first quarter financial results. The live webcast can be accessed via Landec's website on the Investor Events & Presentations page. The web

Recently announced intent to rename and rebrand to Lifecore Biomedical, along with leadership and Board changes Lifecore segment revenues increased 6.9% to $27.6 million in fiscal fourth quarter, and increased 11.5% to $109.3 million for the full fiscal year 2022, as compared to the respective prior year periods Lifecore segment EBITDA increased 14.5% to $8.8 million in fiscal fourth quarter, and increased 16.4% to $28.5 million for the full fiscal year 2022, as compared to the respective prior year periods Lifecore segment adjusted EBITDA increased 15.9% to $8.9 million in fiscal fourth quarter, and increased 17.9% to $28.9 million for the full fiscal year 2022, as compared to the

SANTA MARIA, Calif., July 27, 2022 (GLOBE NEWSWIRE) -- Landec Corporation (NASDAQ:LNDC) ("Landec" or the "Company"), a diversified health and wellness company focused on its growing Lifecore Biomedical ("Lifecore") business – a fully integrated contract development and manufacturing organization ("CDMO") that offers highly differentiated capabilities in the development, fill and finish of complex sterile injectable pharmaceutical products in syringes and vials – today announced that it will host a conference call to discuss fiscal 2022 fourth quarter financial results. The live webcast can be accessed via Landec's website on the Investor Events & Presentations page. The webcast will be ava

Lifecore segment revenues increased 27.9% in fiscal third quarter, as compared to prior year period Reiterates fiscal 2022 full year guidance SANTA MARIA, Calif., April 05, 2022 (GLOBE NEWSWIRE) -- Landec Corporation (NASDAQ:LNDC) ("Landec" or the "Company"), a diversified health and wellness company with two operating businesses, Lifecore Biomedical, Inc. ("Lifecore") and Curation Foods, Inc. ("Curation Foods"), reported results for the fiscal 2022 third quarter ended February 27, 2022. As previously reported, on December 13, 2021 the Company closed on the sale of its Curation Food's fresh packaged salads and vegetables business (the "Eat Smart Disposition"), and as such, those results

SANTA MARIA, Calif., March 22, 2022 (GLOBE NEWSWIRE) -- Landec Corporation (NASDAQ:LNDC) ("Landec" or the "Company"), a diversified health and wellness company focused on its growing Lifecore Biomedical ("Lifecore") business – a fully integrated contract development and manufacturing organization ("CDMO") that offers highly differentiated capabilities in the development, fill and finish of complex sterile injectable pharmaceutical products in syringes and vials – will host a conference call to discuss fiscal 2022 third quarter financial results. The live webcast can be accessed via Landec's website on the Investor Events & Presentations page. The webcast will be available for 30 days. Dat

Reiterates Fiscal 2022 Guidance for Lifecore Provides Pro Forma Curation Foods Segment Results and Updates Guidance for Continuing Segment Operations SANTA MARIA, Calif., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Landec Corporation (NASDAQ:LNDC) ("Landec" or the "Company"), a diversified health and wellness company with two operating businesses, Lifecore Biomedical, Inc. ("Lifecore") and Curation Foods, Inc., reported results for the fiscal 2022 second quarter ended November 28, 2021. Subsequent to fiscal second quarter end, on December 13, 2021 the Company closed on the sale of its Curation Food's fresh packaged salads and vegetables business (the "Eat Smart Disposition") for $73.5 million in c

Strategic sale results in a CDMO-focused company aligned with attractive growth categories and end marketsNet proceeds from the sale will be allocated towards debt pay down, resulting in significant deleveragingAnnounces fiscal second quarter earnings call on January 5, 2022 SANTA MARIA, Calif., Dec. 13, 2021 (GLOBE NEWSWIRE) -- Landec Corporation (NASDAQ:LNDC) ("Landec" or the "Company"), a diversified health and wellness company focused on its growing Lifecore Biomedical ("Lifecore") business – a fully integrated contract development and manufacturing organization ("CDMO") that offers highly differentiated capabilities in the development, fill and finish of complex sterile injectable ph

Quarterly net loss of $9.5 million, EBITDA of $1.1 million, and Adjusted EBITDA of $4.4 millionReiterates Fiscal Year 2022 Guidance SANTA MARIA, Calif., Sept. 29, 2021 (GLOBE NEWSWIRE) -- Landec Corporation (NASDAQ:LNDC), a diversified health and wellness company with two operating businesses, Lifecore Biomedical, Inc. and Curation Foods, Inc., reported results for the fiscal 2022 first quarter ended August 29, 2021. Looking forward, Landec's strategy to continue to create shareholder value is to seek to deliver against its long-term targets, strengthen its balance sheet, drive top-line growth at Lifecore, and selectively invest in innovation and growth while implementing strategic priori

SANTA MARIA, Calif., Sept. 15, 2021 (GLOBE NEWSWIRE) -- Landec Corporation (NASDAQ:LNDC), a diversified health and wellness company with two operating businesses, Lifecore Biomedical, Inc. and Curation Foods, Inc., will hold a conference call on Wednesday, September 29, 2021 at 2 p.m. Pacific time to discuss its results for the fiscal first quarter 2022. Financial results will be reported for the 2022 fiscal first quarter ended August 29, 2021 after market close on September 29, 2021. Landec's President and CEO, Dr. Albert Bolles, will host the Conference Call with John Morberg, Chief Financial Officer and Jim Hall, Lifecore President. A question and answer period will follow the presenta

Lifecore Biomedical Generates Full Year Revenue Growth of 14.3%, Net Income Growth of 23.1%, and Adjusted EBITDA Growth of 22.0%Curation Foods Achieves Fiscal Fourth Quarter Gross Margin of 11.9% on Revenue of $114.0 MillionLandec Consolidated Full Year Revenues of $544.2 Million, Net Loss of $32.7 Million, and Adjusted EBITDA of $31.4 Million SANTA MARIA, Calif., July 28, 2021 (GLOBE NEWSWIRE) -- Landec Corporation (NASDAQ:LNDC), a diversified health and wellness company with two operating businesses, Lifecore Biomedical, Inc. and Curation Foods, Inc., reported results for the fiscal 2021 fourth quarter and full fiscal year ended May 30, 2021. Looking forward, Landec's strategy to cont